USE OF CANNABINOIDS IN COMBINATION WITH AN ANTI-PSYCHOTIC MEDICAMENT

摘要

Disclosed herein is the use of tetrahydrocannabivarin (THCV) and/or cannabidiol (CBD), together with an atypical anti-psychotic medicament which is a dopamine-serotonin system stabilizer in the manufacture of a pharmaceutical formulation for use in the prevention or treatment of psychosis or a psychotic disorder, wherein the THCV and/or CBD are administered separately, sequentially or simultaneously to the atypical anti-psychotic medicament which is a dopamine-serotonin system stabilizer, so as to reduce or remove undesirable side effects of the atypical anti-psychotic medicament and / or provide additional anti-psychotic effects, wherein the atypical anti-psychotic medicament which is a dopamine-serotonin system stabiliser is aripiprazole or a metabolite of aripiprazole. Particularly preferred psychosis or psychotic disorders to be treated is taken from the group: schizophrenia; schizophreniform disorder; schizoaffective disorder; bipolar I disorder; bipolar II disorder; major depressive disorder with psychotic feature; delusional disorders; Shared Psychotic Disorder; Brief Psychotic disorder; Psychotic disorder not otherwise specified; paranoid personality disorder; schizoid personality disorder; and schizotypal personality disorder.